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ABSTRACT
Background Unplanned readmissions to hospital are
used in many healthcare systems as a quality indicator of
care. Identifying patients at risk of readmission is
difﬁcult; existing prediction tools are only moderately
sensitive. Correlations exist between certain medicines
and emergency readmission, but it is not known
whether the association is direct or indirect.
Objectives To determine whether person-centred
pharmaceutical care bundles, comprising individualised
medicines information, risk management and/or support
in taking medicines, might prevent unplanned
readmissions by improving adherence and reducing
avoidable harm from prescribed medications.
Methods We designed and implemented person-
centred pharmaceutical care bundles for patients who
were socially isolated and/or on high-risk medicines on
one older people’s medical ward for 1 year from
February 2013. Another ward with similar patient
demographics, service characteristics and a standard
clinical pharmacy service was used as a comparator in a
prospective cohort study. Readmission rates were
retrospectively studied for 12 months before the
intervention and during the 12-month intervention
period.
Results The readmission rates for the intervention and
control wards in the 12 months before the intervention
were not signiﬁcantly different. During the intervention
period, the readmission rate was signiﬁcantly lower on
the intervention ward (69/418) than on the control ward
(107/490; 17% vs 22%, p<0.05, z=2.05, two-sample z
test for difference in proportions of unrelated samples).
Conclusions Person-centred pharmaceutical care
bundles were signiﬁcantly associated with reduced risk of
emergency hospital readmission in this study. Further
evaluation of the model is warranted.
INTRODUCTION
Unplanned readmission to hospital is used in many
healthcare systems as a quality indicator because
some will be the result of poor inpatient care or
badly organised support or rehabilitation after dis-
charge. The proportion of readmissions that are
avoidable is difﬁcult to specify as the criteria out-
lined in published studies, used to determine
whether an admission was avoidable, are often
subjective.1
As an incentive to improve inpatient care and
discharge process quality, English National Health
Service (NHS) acute care hospital Trusts face ﬁnan-
cial penalties as a consequence of emergency read-
missions.2 The UK Department of Health, and thus
the deﬁnition used in this paper, deﬁnes emergency
readmissions as unplanned hospital admissions
occurring within 30 days of the previous, last
hospital discharge, but excluding admissions for
malignant cancer, cancer chemotherapy or specialist
obstetric or mental health services. Numbers of
emergency readmissions are collected routinely in
the UK as part of each Trust’s Hospital Episode
Statistics, the means by which Trusts are paid for
the care they provide. The data are also used at a
local and national level for resource management,
information and clinical governance.
Clinicians and managers working to reduce read-
missions in the UK face a number of challenges.
The majority of the published evidence around
hospital readmissions comes from health settings in
the USA or Canada and may not be directly trans-
ferable to the UK.3 4 In addition, identifying
patients at risk of readmission is difﬁcult; health-
care and social care professionals are unable to
accurately predict which individual patients will be
readmitted5 6 and prediction tools for hospital
readmission within 30 days have moderate sensitiv-
ity at best3 although certain prediction tools may
be more discriminatory in particular patient popu-
lations.7 8 Although multiple hospital admissions
are demonstrably associated with future admission,9
modelling with patient-speciﬁc factors such as
medical conditions rather than epidemiological
factors does not appear to increase the sensitivity
of readmission prediction tools for medical
patients;10 11 this suggests that the health belief
model and health behaviours of individuals might
be important factors in readmission. A further chal-
lenge lies in preventing the readmissions that have
been predicted; staff resource is increasingly under
pressure in the NHS because of ongoing cost-saving
programmes but proven interventions tend to be
resource intensive, particularly if conducted in the
patient’s home.3
Newcastle upon Tyne Hospitals NHS Foundation
Trust (henceforth referred to as the Trust) is an
1800 bed teaching hospital in the North of
England. Data from the Ofﬁce for National Statistics
show that our local population has some of the
highest deprivation indices and lowest life expectan-
cies in the UK. A 2012 audit of readmissions occur-
ring in 1 week within the Trust identiﬁed medicines
as a causal/contributing factor in 16 of 81 cases
(20%). Twelve of those medication-related readmis-
sions (75%) were judged by a multidisciplinary team
to have been avoidable. Weak-to-moderate correla-
tions can be found in the literature between certain
medications and likelihood of readmission, namely,
corticosteroids, psychoactive agents especially
opioids, anti-epileptics, anti-neoplastics, immune-
modulating agents, non-steroidal anti-inﬂammatory
agents, anticoagulants, diuretics, drugs acting on the
renin–angiotensin–aldosterone system and anti-
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diabetic agents including insulin,12–14 but it is not known
whether those medicines are causal factors in readmission. The
correlation may be an indirect association between those medica-
tions and long-term conditions such as heart failure or chronic
obstructive pulmonary disease that are known to have high
healthcare use and be associated with polypharmacy.
Polypharmacy (deﬁned as ﬁve or more prescribed medi-
cines),15 poor discharge planning,16 poor communication with
the patient,17 or the primary care team,18 at transfer of care and
inadequate follow-up by the hospital19–21 have been found in
observational studies to result in adverse patient outcomes
including unplanned or avoidable readmission.22 It is therefore
plausible that the behaviours of healthcare professionals and/or
patient-speciﬁc factors such as medical condition(s) and adher-
ence to treatment(s) may be more accurate predictors of hospital
readmission risk than the individual’s epidemiological group-
ing.23 The majority of effective interventions identiﬁed from the
literature were face-to-face and person-centred; ﬁve key themes
emerged from our literature review and are shown in ﬁgure 1.
Our hypothesis was that person-centred pharmaceutical care
during and after a hospital admission, that is meeting each indi-
vidual’s need for information, risk management or support to
take their medicines, may reduce the rate of emergency readmis-
sions caused by non-adherence or troublesome side effects.
Traditionally, encounters between clinical pharmacists and
patients have been pharmacist led with the goal of giving infor-
mation. In our new pharmaceutical-care model, the encounters
between the clinical pharmacists and patients were conversations
led by patients where pharmacists spent more time listening
than talking and the goal was to help the patient and carer share
treatment decisions and ﬁnd solutions to any problems identi-
ﬁed. In addition, person-centred pharmaceutical care bundles
were developed by the clinical pharmacy team for each of the
medication types known to be correlated with readmission; two
are shown as illustrative examples in ﬁgures 2 and 3. Existing
national or local procedures for medication risk minimisation,
such as National Patient Safety Agency (NPSA) guidance, were
built into the care bundles.
Although a large number of person-centred interventions
designed to reduce emergency readmissions were identiﬁed in
the literature, description or evaluation of the intervention was
often vague or absent from the original articles. The clinical
pharmacy team mapped the risks associated with a medical
admission or transfer of care for older people, identiﬁed
interventions that had demonstrated effectiveness for managing
those risks (eg, Teach-back,24 careful medicine reconciliation,
shared decision making, motivational interview techniques, real-
time discharge communication, assessing a person’s usual
support network for suitability, providing person-centred infor-
mation) and incorporated these into a patient-level document to
be used alongside and to record completion of the pharmaceut-
ical care bundles. A standard operating procedure (SOP) was
chosen as the mechanism for introducing the care bundles to
pharmacy practice because the pharmacy team was already
familiar with the beneﬁts of SOP on controlling variation in pro-
cesses. A detailed description of the intervention, patient assess-
ment tool and pharmaceutical care bundles can be accessed as
an online supplementary ﬁle.
Hospital pharmacy staff are well placed to identify and
address these needs during an admission, but are often not
resourced or commissioned to provide domiciliary services after
hospital discharge. The New Medicines Service (NMS) and tar-
geted Medicines Use Reviews (MUR) are Community Pharmacy
services designed to address a person’s medication-related needs
and are UK NHS funded in a broad range of circumstances
including recent hospital discharge.25 The opportunity exists for
hospital and community pharmacy teams to join-up to provide
person-centred pharmaceutical care across the primary–second-
ary care interface.26
This paper describes the effect of introducing the intervention
on an older people’s medical ward in a prospective, cohort
study design.
METHODS
Ethical consideration
This was an observational study that assessed the effectiveness
of a service improvement on readmission rather than imple-
menting a new regimen of treatment and therefore full ethical
approval was not required for this exercise. The study complies
with the relevant principles of good practice in research and
data protection.
The intervention and patient record
To maximise the chances of successful adoption by the phar-
macy team, pharmacy staff working on the intervention ward
were engaged as key stakeholders in the design and testing of
the person-centred pharmaceutical care bundles, SOP and a
patient-level document to record care-bundle completion.27
Figure 1 Key themes identiﬁed as effective components in preventing readmissions. NMS, New Medicines Service; MUR, Medicines Use Reviews.
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The patient-level documentation was designed according to the
Trust standard format and reﬁned after piloting to make it as
quick and easy to complete as possible; a time–motion observa-
tion of the pharmacy technician working with ﬁve patients sug-
gests that 10 min per patient was required to complete the
document.
Each patient admitted to the intervention ward was screened
by the pharmacy team as prescribed by the SOP and the phar-
macy team implemented any relevant care bundles during the
patient’s stay and at discharge. Patients who had a longer stay
on the ward were rescreened once a week using the SOP to
identify any new medication-related risks or changes to dis-
charge plans. Patients discharged from the intervention ward
were offered a referral to their community pharmacy for NMS
or MUR if they met the eligibility criteria; patients who met the
eligibility criteria, but could not receive the service because they
were housebound were offered the same services delivered by
the hospital pharmacy team.
Description of the patients and pharmacy staff on the
intervention and control wards
Two wards specialising in the care of medical patients over
80 years of age with similar service statistics (Healthcare
Resource Groups28 and average length of stay) were identiﬁed
for the study; one was selected at random to be the intervention
ward and patients were consequently allocated non-
experimentally to either the intervention or control ward by the
hospital bed management team who were unaware that a study
was taking place. Both wards already had a named pharmacist
for 5 days per week who performed medicines reconciliation
after admission, some patient education and clinical medication
review. Fifteen hours per week of pharmacy technician time was
allocated to the intervention ward to deliver the intervention in
conjunction with the pharmacist. To minimise confounding, the
pharmacy technician did not work on the control ward and
pharmacists working on the control ward were prevented from
seeing the person-centred pharmaceutical care bundles or the
individual patient checklist.
Data and variables
Readmission rates and average length of stay were obtained for
each ward from the Trust Informatics Department; these are
routinely collected monthly hospital activity data. The data for
pharmaceutical care bundle completion rate for the intervention
period and the numbers of patients requiring a home visit or
telephone call after discharge were retrospectively collected
from each patient-level record card. Medicine reconciliation rate
was audited biannually for routine performance reports by a
pharmacist unrelated to the study. Patient and general practi-
tioner (GP) feedback was captured by self-administered postal
questionnaire over 2 months of the intervention period; the
questionnaires were deliberately short and contained a ﬁrst-class
stamped, addressed envelope to help secure a good response
rate. The data were analysed by a researcher with statistical
Figure 2 Person-centred pharmaceutical care bundle for opioids.
Figure 3 Person-centred pharmaceutical care-bundle for corticosteroids. COPD, chronic obstructive pulmonary disease; NMS, New Medicines
Service. FRAX is the name of a published tool, the FRAX(R) tool, available at https://www.shef.ac.uk/FRAX/tool.jsp
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expertise. As this was a natural experiment without randomisa-
tion and with an unknown effect size, formal sample size calcu-
lation was not considered. The data obtained from this study
will help to power a future trial. A 12-month intervention
period was selected to evaluate sustainability of the model and
eliminate the possibility of confounding by seasonal variations
in readmission rate.
Analysis
Using summary data for before and during intervention period,
estimates of risk difference, OR were estimated by a researcher
with statistical expertise. Breslow–Day and Tarone’s statistics test
was used to test for homogeneity of OR from during and before
intervention periods. Fisher’s exact test was used to analyse
available data for intervention period to examine whether pro-
portion of readmission varied by the different components of
treatment plan. The analysis was done separately for interven-
tion and control ward, as well as for examining overall (com-
bined for both ward) difference in proportion readmitted by the
different components. Logistical regression analysis was done to
examine whether readmission rate varied signiﬁcantly between
intervention and control wards and also to identify variables
that were signiﬁcantly associated with readmission (control for
other variables). IBM SPSS Statistics, V.20 was used to analyse
the data. The qualitative data from patient and GP question-
naires are simply described.
RESULTS
Outcome measures
During the intervention, readmission rate was 5% lower in
intervention ward in comparison with that of the control ward
(table 1). The odds of readmission for the control ward was
41% higher than the odds of readmission for the intervention
ward during the intervention period (OR=1.41, 95% CI 1.01
to 1.98). However, the control ward had lower odds of readmis-
sion than the intervention ward at baseline (OR=0.82, 95% CI
0.56 to 1.14). The Breslow–Day and Tarone’s test examined the
homogeneity of OR between the two periods and found that
they were signiﬁcantly different. This qualitative interaction sug-
gests that the intervention may have a positive impact on hos-
pital readmission. Therefore, the subsequent analyses were done
for the data obtained during the intervention period only to
identify risk factors for hospital readmissions.
Figure 4A shows the variability in monthly readmission rates
for the intervention and control wards in the months before the
intervention; ﬁgure 4B shows the same parameters during the
intervention period; the intervention ward has lower readmis-
sion rates than the control ward for 10 of the 12 months of the
intervention period.
Average length of stay did not change signiﬁcantly on either
ward during the intervention period. Medicines reconciliation
after admission was recorded for 100% of patients sampled on
both the intervention and control wards in both biannual audit
periods.
In the intervention ward, readmission was signiﬁcantly asso-
ciated with monitored dosage system (MDS) use (readmis-
sion=16.8% and 7.4% among service users vs non-service
users, respectively; risk difference=9.4%; p=0.03) and whether
the discharge medication list was sent in real time or not
(22.7% vs 7.9% among service users and non-service users,
respectively; risk difference=14.8%; p<0.001). ORs for these
factors are shown in table 2. However, there was no signiﬁcant
difference in readmission rate for the other treatment compo-
nents (all p>0.05). Multivariable logistical regression analysis
showed that controlling for other factors (MDS use, require-
ments of self-medication assessment, sending discharge medicine
in real time), the likelihood of patients being readmitted was
less where pharmacy staff completed actions prescribed by the
SOP compared with patients who were discharged before the
prescribed actions were completed (OR=0.539, 95% CI 0.299
to 0.969; p=0.039).
An average of three patients per month required follow-up
after discharge by the hospital pharmacy team. Ninety per cent
of follow-up was possible by telephone and the telephone calls
Table 1 Readmissions within 30 days for the intervention and control wards before and during the intervention
Control ward Intervention ward
Two sample z-test for difference
in population proportionsPatient numbers Discharges Readmissions Discharges Readmissions
12-month period prior to intervention 446 72 (16.1%) 403 78 (19.4%) Not significantly different
12-month intervention period 490 107 (21.8%) 418 69 (16.5%) z=2.05, p=0.041
Pearson’s goodness-of-fit χ2 test for difference in proportions Not significantly different
χ2=3.33, p=0.068
Not significantly different
χ2=1.52, p=0.375
Figure 4 Readmission rate (%) for the intervention and control wards
before (A) and during (B) the intervention.
4 Blagburn J, et al. Eur J Hosp Pharm 2015;0:1–6. doi:10.1136/ejhpharm-2015-000736
Original article
group.bmj.com on October 2, 2015 - Published by http://ejhp.bmj.com/Downloaded from 
typically lasted around 5 min. Home visits typically lasted
around 20 min plus travelling time. All patients who replied to
our postal questionnaire (13 respondents, response rate 43%)
accepted the telephone follow up or home visits from hospital
pharmacy staff and 12 of 13 (92%) reported that they found the
pharmacy technician’s advice helpful. We referred an average of
15 patients per month to community pharmacies for NMS or
MUR, but uptake of those services was not monitored. Thirty
GPs (response rate 71%) replied to our postal questionnaire.
Approximately half (14, 47%) of the GP respondents agreed that
the discharge information we provided about medicines was
more accurate and timely than they would typically receive.
DISCUSSION
Our results suggest that the risk of medication-related readmis-
sions can be reduced with person-centred pharmaceutical care
and that pharmaceutical care bundles are a practicable way to
introduce person-centred care with medicines to an acute teach-
ing hospital in the UK NHS.
Our study has several limitations relating to the design and
conduct. For pragmatic reasons, our primary outcome measure
was obtained from clinical coding data, which is known to
contain inaccuracies; a recent audit conducted on behalf of the
UK Department of Health identiﬁed wide inter-Trust coding
error variation with an average error rate of 7%.29 Patients were
not involved in the design of the study and their perspectives
may have caused us to alter the design or delivery of the inter-
vention. As a cohort study, there may be factors inﬂuencing
readmission rate that we cannot measure or control. For
example, the two wards in our study have different lead clini-
cians; those clinicians may impact the culture of the ward and
subsequently on discharge planning and readmissions, but that
effect would be difﬁcult to quantify objectively. Loss to
follow-up can be a difﬁculty in cohort studies, but was not a
major issue in this study. We hypothesise that this is the result of
the need for planned discharge in this patient group, which typ-
ically occurs within usual working hours because support ser-
vices are often unavailable outside those hours. Only one
patient was transferred from the intervention to the control
ward in the 12-month intervention period, those data have not
been excluded from our results, but are unlikely to have an
effect on our primary outcome measure. We did not examine
the sociodemographic or socioeconomic characteristics of
patients on the intervention or control wards; although there is
no reason to expect a difference, this potentially confounds our
results.
The apparent reduction of readmission rate in our study
should be received cautiously for the reasons described above
and because the study was not powered to detect this difference.
The prolonged period where the readmission rate for the inter-
vention ward was lower than control ward (ﬁgure 4B) is
unusual behaviour for readmission rates and suggests that the
intervention was having an effect. Interestingly, the magnitude
of the observed difference is similar to that observed in Leeds
Teaching Hospitals IMPACT study where hospital pharmacy
joined up with community pharmacy at transition of care in a
similar patient group.30
The association between MDS use and increased risk of
readmission observed in our study is interesting and warrants
further investigation. The association may be the indirect result
of the characteristics of patients who are provided with MDS
(often people vulnerable to adverse drug events because of poly-
pharmacy or cognitive impairment) or the direct result of MDS
removing a link between patients and their medicines. The asso-
ciation we observed between real-time discharge communication
and increased risk of readmission is possibly also a reﬂection of
the impact of MDS use; the intervention SOP directed phar-
macy staff to real-time discharge communication for patients
with MDS and/or district nurse support with insulin to reduce
dosing errors as a result of changes made in hospital.
The wards chosen for this study are typical of acute medical
wards for older people in UK teaching hospitals but our results
may not be transferable outside this speciality.
Key messages
What is already known on this subject
▸ Readmission risk prediction models are widely used but not
sensitive.
▸ A number of medications are correlated with readmission
but a causal link is not established.
What this study adds
▸ Person-centred risk assessment and risk management for
older people and their medications in hospital may reduce
the likelihood of 30-day readmission by 40%.
▸ Using a monitored dosage system for medicines at home
may be a signiﬁcant risk factor for hospital readmission.
Twitter Follow Julia Blagburn at @juliablagburn
Acknowledgements Karen Glasper and Christine Baty, Pharmacy Technicians at
Newcastle upon Tyne Hospitals NHS Foundation Trust. David Grainger, General
Practitioner, Newcastle West Clinical Commissioning Group. Adetayo Kasim,
Research Statistician, Wolfson Research Institute for Health and Wellbeing, for
providing support with statistical analysis.
Contributors Planning of the study including literature search and design of the
intervention and data collection tools was done by JB and BK-F. The study was
conducted by JB and KG. Statistical design and analysis was done by NA and AK.
JB drafted the article which was revised by AH, BK-F, DG and AK.
Funding Newcastle West Clinical Commissioning Group supported this study by
funding a Pharmacy Technician for 15 h per week for 1 year.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Anonymised data are available on request from the
corresponding author.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Table 2 Multivariate logistical regression analysis examining
factors associated with readmission
Indicators OR
95% CI
Lower Upper
Intervention effect (ward) 0.539 0.299 0.969
Uses MDS 1.619 0.903 2.905
Self-medication assessment required 0.494 0.271 0.898
Discharge medication list sent in real time 2.423 1.359 4.322
Constant 0.166
MDS, monitored dosage system.
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